NCT02251210已完成2 期
Three Month, Randomised, Double-blind, Double-dummy, Placebo-controlled, Multiple Dose-range Study of the Efficacy and Safety of BIIL 284 BS (5, 25 and 75 mg p.o. Once Daily) in Adult Patients With Active Rheumatoid Arthritis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 404
- 主要终点
- Percentage of patients achieving 20% improvement assessed by the American College of Rheumatology (ACR) criteria (ACR20)
研究概览
简要总结
To investigate efficacy and safety of 3 doses of BIIL 284 BS in active rheumatoid arthritis (RA) and determine the dose with most positive efficacy / safety ratio. Pharmacokinetic profile will be also obtained.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients of >=18 and <= 70 years of age
- •Patients suffering from rheumatoid arthritis as defined by the American Rheumatism Association (ARA) criteria revised 1987 and date of diagnosis >= 6 months. At least 4 of the following 7 criteria must be present:
- •Morning stiffness in and around the joints lasting at least 1 hour before maximal improvement for at least 6 weeks
- •Arthritis (soft tissue thickening or fluid - not bony overgrowth alone) of at least 3 joint areas for at least 6 weeks
- •Arthritis of hand joints (at least one area swollen in a wrist, metacarpophalangeal (MCP) or proximal interphalangeal (PIP) joint) for at least 6 weeks
- •Symmetrical arthritis (observed by a physician) with simultaneous involvement of the joints on both sides of the body for at least 6 weeks
- •Rheumatoid nodules (observed by a physician) over bony prominence or extensor surfaces or in juxta-articular regions
- •Serum rheumatoid factor positive
- •X-ray changes typical of rheumatoid arthritis (erosions or unequivocal bony decalcification localized in or most marked adjacent to the involved joints)
- •Patients belonging to the RA functional class I, II or III
- •Active RA as defined at visit 2 by:
- •Swollen joint count at least of 6 (of 28 joints examined) and
- •Tender joint count at least of 8 (of 28 joints examined) and
- •Patients must fulfil 2 out of the 3 following criteria:
- •Patient's assessment of pain (VAS) >= 40 mm
- •Investigator's global assessment of disease activity on a VAS >= 40 mm
- •ESR >= 28 mm/h or CRP >= 20 mg/L
- •Patient's written informed consent obtained at Visit 1 (screening) before enrolment in the study
排除标准
- •Patient presenting or having a history of inflammatory rheumatic disease other than RA (e.g.: mixed connective tissue disease, systemic lupus erythematosus, seronegative spondyloarthropathy)
- •Patients who have failed to more than 3 different disease-modifying antirheumatic drug (DMARDs) therapies previously due to lack of efficacy (in case of combined therapy each DMARDs used is counted as one)
- •Patients with any other disease that could interfere with the evaluation of efficacy and safety
- •Patients in treatment with any DMARDs / slow-acting anti-rheumatic drug (SAARDs) during the periods specified:
- •4 weeks before V2: Methotrexate, parenteral/oral gold, D-penicillamine, Sulphasalazine, antimalarials (e.g.:Chloroquine/Hydroxychloroquine), Azathioprine, Cyclosporine A, Alkylating agents (e.g.: Cyclophosphamide / Chlorambucil), Minocycline, Etanercept (Enbrel®), and Leflunomide (only if wash-out with Colestyramine has been done after leflunomide discontinuation)
- •3 months before Visit 2: Leflunomide if no wash- out with colestyramine has been done after leflunomide discontinuation, Infliximab (Remicade®), any other biological compound.
- •Patient in treatment with oral corticosteroids at a dose higher than 10 mg/day or 0.2 mg/Kg/day (prednisone equivalent) whichever is lower, during the 4 weeks prior to Visit 2, change in the treatment with oral corticosteroids during the 4 weeks prior to Visit 2 or intended change during the trial
- •Patients in treatment with any parenteral (intravenous, intramuscular or intraarticular) treatment with corticosteroids during the 4 weeks prior to Visit 2 or their intended use during the trial.
- •Change in treatment with non-steroidal anti-inflammatory drugs (NSAIDs) during the 2 weeks prior to Visit 2 or any intended change during the trial.
- •Synovectomy, and/or surgical treatment for RA in the previous 3 months prior to visit 2 or intended indication during the trial.
- •Synoviorthesis in the previous 4 weeks prior to Visit 2 or intended indication during the trial.
- •Patients in treatment with any other leukotriene inhibitors such as montelukast or zafirlukast 4 weeks prior to Visit 2 or intended use during the trial.
- •Initiation of physiotherapy during the 2 weeks before V2, or intended change during the trial
- •Patients with history of cardiovascular, renal, neurologic, psychiatric, liver, gastrointestinal (including lactose intolerance ), immunologic or endocrine dysfunction if they are clinically significant.
- •Patients with any other known condition or circumstance, which would in the investigator's opinion, prevents compliance or completion of the study
- •Patients with history of cancer within the past 5 years, excluding treated basal cell carcinoma
- •Patients with chronic infection or acute infections during the 4 weeks before visit 1
- •Patients with known positive serology for hepatitis B or C
- •Patients with anticoagulant treatment (i.e. dicumarol or derivatives, warfarin)
- •Any of the following abnormal laboratory parameters at Visit 2:
- •Impaired hepatic function, defined by serum levels of either Aspartate Aminotransferase (AST)(SGOT), Alanine Aminotransferase (ALT) (SGPT), alkaline phosphatase or bilirubin > 2 x upper limit of normal (ULN)
- •Impaired renal function, defined by serum creatinine > 133 mmol/L (1.5 mg/dl)
- •Hemoglobin values < 10 g/dl
- •White blood cell count <= 3.500 cells/mm3
- •Platelet count of less than 120.000/mm3
- •Severe hypoproteinemia (e.g. in case of severe liver disease or nephrotic syndrome) with albumin < 3.0 g/dl
- •Patients with any other abnormal, clinically relevant laboratory values not related to RA
- •Patients participating in another clinical trial during the 3 months prior to visit 2
- •Previous participation in the randomised period of this study
- •Patients with a significant history and/or active alcohol or drug abuse Significant is defined as that which in the opinion of the investigator may either put the patient at risk because of participation in the study or may influence the results of the study or the patient's ability to participate in the study
- •Pregnancy (to be excluded by pregnancy test at visit 1) or breast feeding, and sexually active women with childbearing potential not using a medically approved method of contraception (i.e. oral contraceptives, intrauterine devices, or double-barrier) for at least one month before and throughout the study period
研究组 & 干预措施
BIIL 284 BS high dose
Experimental
干预措施: BIIL 284 BS high dose (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
BIIL 284 BS low dose
Experimental
干预措施: BIIL 284 BS low dose (Drug)
BIIL 284 BS medium dose
Experimental
干预措施: BIIL 284 BS medium dose (Drug)
结局指标
主要结局
Percentage of patients achieving 20% improvement assessed by the American College of Rheumatology (ACR) criteria (ACR20)
时间窗: 3 months
次要结局
- Patient's global assessment of disease activity by VAS(up to 3 months)
- Investigator's global assessment of disease activity by VAS(up to 3 months)
- Change in erythrocyte sedimentation rate (ESR)(up to 3 months)
- Change in C-reactive protein (CRP)(up to 3 months)
- Change in Quality of Life(baseline, 3 months)
- Percentage of patients achieving 50% improvement (ACR50)(3 months)
- Number of withdrawals due to lack of efficacy(up to 3 months)
- Number of swollen joints(up to 3 months)
- Number of tender joints(up to 3 months)
- Patient's assessment of physical function(up to 3 months)
- Patient's assessment of pain on a visual analog scale (VAS)(up to 3 months)
- Change in Disease Activity Score (DAS 28)(baseline, up to 3 months)
- Change in duration of morning stiffness(up to 3 months)
- Consumption of rescue medication(up to 3 months)
- Number of patients with adverse events(up to 3 months)
- Number of withdrawals due to adverse events(up to 3 months)
- Final global assessment of tolerability by investigator on a 4-point scale(3 months)
- Patient's assessment of fatigue by VAS(up to 3 months)
- Number of patients with clinically significant changes in laboratory findings(up to 3 months)
- Number of patients with clinically significant changes in vital signs(up to 3 months)
- Number of patients with clinically significant changes in 12-lead ECG(3 months)
研究者
相似试验
已完成
2 期
The Effect of BIIL 284 BS on Induced-sputum Variables in Patients With Bronchial AsthmaAsthmaNCT02249312Boehringer Ingelheim38
已完成
3 期
A Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Active Rheumatoid ArthritisRheumatoid ArthritisNCT00299130Genentech, Inc.511
已完成
1 期
Effect of BIIL 284 BS on the Pharmacokinetics of Theophylline in Healthy Male VolunteersHealthyNCT02273440Boehringer Ingelheim16
已完成
1 期
Multiple Ascending Dose Study of BMS-582949 in Patients With Stable Rheumatoid Arthritis on the Methotrexate BackgroundRheumatoid ArthritisNCT00162292Bristol-Myers Squibb33
已完成
2 期
BI 44370 TA in Acute Migraine AttackMigraine DisordersNCT00751803Boehringer Ingelheim416